ArticleScientific reports2025

KDM6A deficiency promotes tumor progression and resistance to cabozantinib treatment in clear cell renal cell carcinoma.

Yuki Kohada et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.